Citation: It. Gram et al., Reversal of gonadotropin-releasing hormone agonist induced reductions in mammographic densities on stopping treatment, CANC EPID B, 10(11), 2001, pp. 1117-1120
Citation: Dv. Spicer et Mc. Pike, Future possibilities in the prevention of breast cancer - Luteinizing hormone-releasing hormone agonists, BREAST CA R, 2(4), 2000, pp. 264-267
Authors:
Roberts, JD
Shibata, S
Spicer, DV
McLeod, HL
Tombes, MB
Kyle, B
Carroll, M
Sheedy, B
Collier, MA
Pithavala, YK
Paradiso, LJ
Clendeninn, NJ
Citation: Jd. Roberts et al., Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks, CANC CHEMOT, 45(5), 2000, pp. 423-427
Authors:
Roberts, JD
Poplin, EA
Tombes, MB
Kyle, B
Spicer, DV
Grant, S
Synold, T
Moran, R
Citation: Jd. Roberts et al., Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation, CANC CHEMOT, 45(2), 2000, pp. 103-110